They observed that patients with PD-L1 TC (tumor cell) expression <1% had an OS of 15 months (95% CI,10.5–27.4) when given durvalumab plus DT vs 11.7 months when given durvalumab plus chemotherapy. This evidence concerns the gene CD274 and neoplasm.